MedTrace Logo

Montelukast for Prevention & Treatment of OHSS

NCT03794037 · Status: SUSPENDED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-09-21

No results posted yet for this study

Summary

montelukast \& dydrgesteron will be given to cases with suspected or proven ovarian hyperstimulation in one group in comparison with dydrogesteron alone in the other group.

Conditions

  • Ovarian Hyperstimulation Syndrome

Interventions

DRUG

dydrgesterone 10 mg( tab)/12hs/14 days

Dydrogesterone Oral Tablet 10 mg twice daily for 14 days to be taken from the day of ovum pickup

COMBINATION_PRODUCT

montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days

montelukast 10 mg(tab) once daily oral for 7 days \& dydrgesterone 10 mg (tab) twice daily oral for 14 days \&

Sponsors & Collaborators

  • Hawaa Fertility Center

    collaborator OTHER

  • Benha University

    lead OTHER

Principal Investigators

  • ahmed sa saad, MD, ph D · Hawaa Fertility Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
37 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-05
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03794037 on ClinicalTrials.gov